Designing Novel Brain Drugs with Xylo Bio
Human 3 with Brom and Sam8 Heinä 2025

Designing Novel Brain Drugs with Xylo Bio

Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturally occurring psychedelic drugs but are specifically designed to not induce hallucinations. Xylo's cofounders Josh Ismin and Sam Banister join Brom Rector and Sam Tabone to discuss:


(3:25) - Xylo origins + why design novel psychedelic molecules?

10:30) - How Xylo’s AI approach is different than other non-hallucinogenic psychedelic companies like Gilgamesh and Delix

(21:30) - What is the head twitch response?

(25:30) - How Xylo’s drugs are different than other psychedelics even though they hit the same receptor (5HT2a)

(26:30) - How Lykos’ failure to get MDMA approved impacts Xylo

(32:00) - Running trials in Australia

(43:00) - How has Xylo has evolved over the years

(50:30) - How will AI change drug discovery

(53:00) - How much of the neuro receptor space has been characterized

(56:00) - Is Xylo bullish or bearish on AIMore on Xylo here: https://www.xylo.bio/


More on Brom, Sam and XEIA here: www.xeiavp.com

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(32)

$HIMS Q2 Results - our take as healthcare venture capitalists

$HIMS Q2 Results - our take as healthcare venture capitalists

Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. W...

5 Elo 20251h 24min

Investing in Psychedelic BioTech [August 2025 webinar replay]

Investing in Psychedelic BioTech [August 2025 webinar replay]

Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP2025 has been the start of a bull period for psychedelic medicine.​Psychedelic Biotechs like GH Research, Compass ...

30 Heinä 202558min

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

The past few years have been rough for psychedelic and shroom stocks, but recent news from ATAI (and Recognify), Compass Pathways and GH Research + positive regulatory tailwinds from RFK and MAHA make...

29 Heinä 202516min

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Ryan Field is the CEO of Kernel, a brain-computer interface company founded by Bryan Johnson. Kernel is a cutting edge, non-invasive BCI that uses fNIRS to image the brain. Imagine if getting an MRI w...

22 Heinä 20251h 33min

How to start a VC fund

How to start a VC fund

I interviewed Michael Huseby to learn about his life story and his new book: Fundamentals: Your Friendly Guide to Investment Funds and SyndicationsThis is a great listen for anyone interested in start...

15 Heinä 20251h 20min

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Replay of our webinar on investing in brain computer interfaces. Join our upcoming July 30th event on investing in psychedelic biotech: psybio.org

12 Heinä 20251h 9min

The BioIndustrial Revolution: Why Peter Thiel and Chris Sacca backed Arye's Biomanufacturing Startup

The BioIndustrial Revolution: Why Peter Thiel and Chris Sacca backed Arye's Biomanufacturing Startup

Arye Lipman is the cofounder of Biosphere, a startup that recently raised millions of dollars from Peter Thiel's Founders Fund and Chris Sacca's Lower Carbon Capital to Unleash Industrial Biomanufactu...

30 Kesä 20251h 20min